Clinical Report of the Effectiveness of Netasurdil in Patients with Uveitic Glaucoma

ABSTRACT

The use of netasurdil 0.02% (Rhopressa) in patients with primary open-angle glaucoma has been shown to be effective in lowering intraocular pressure (IOP). However, the effectiveness of netasurdil in patients with secondary forms of glaucoma has been minimally investigated. Previous reports have suggested its adequacy in lowering IOP in patients with congenital glaucoma. Its effectiveness in treating uveitic glaucoma, on the other hand, has yet to be formally examined. In a small group of patients with uveitic glaucoma, netasurdil has been shown to lower IOP by an average of 10.0mmHg, with over half of patients exhibiting more than a 20% decrease in IOP after 12 months of treatment. No patients developed any serious complications from taking netasurdil, however, conjunctival hyperemia was present in 15% of the patient population. Early success of netasurdil in patients with uveitic glaucoma warrants further investigation to better understand its safety and effectiveness.

KEYWORDS:

• Effectiveness
• intraocular pressure
• netasurdil
• safety
• uveitic glaucoma

Disclosure statement

Disclosures for Albert S. Khouri: Grant support: Allergan, Optovue, NJ Health Foundation, Speaker Bureau: Aerie, Allergan, Bausch & Lomb. No conflicting relationship exists for the remaining authors.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.